Ambulatory management of common forms of anemia

American Family Physician

Volumn 59, Issue 6, 1999, Pages 1598-1604

  Little, David R ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ASCORBIC ACID; CYANOCOBALAMIN; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FOLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON DEXTRAN; LEVODOPA; METHOTREXATE; METHYLDOPA; NASCOBOL; PENICILLAMINE; PROTON PUMP INHIBITOR; PYRIMETHAMINE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; TRIAMTERENE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANEMIA; DIET SUPPLEMENTATION; DRUG ANTAGONISM; FOLIC ACID DEFICIENCY; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MEAN CORPUSCULAR VOLUME; NEURAL TUBE DEFECT; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERNICIOUS ANEMIA; REVIEW;

AMBULATORY CARE; ANEMIA, IRON-DEFICIENCY; DRUG ADMINISTRATION SCHEDULE; HEMATOCRIT; HEMOGLOBINS; HUMANS; IRON; VITAMIN B 12 DEFICIENCY;

EID: 0033558893     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Current estimates from the National Health Interview Survey, 1994. Hyattsville, Md.: Dept of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Health Statistics, 1995; DHHS publication no. 95-1521.
2. Brown RG. Anemia. In: Taylor RB, ed. Family medicine: principles and practice. 4th ed. New York: Springer-Verlag, 1994:997-1005.
3. Little DR. Diagnosis and management of anemia. Prim Care Rep 1997;3:175-84.
4. Centers for Disease Control and Prevention. Guidelines for school health programs to promote life-long healthy eating. MMWR Morb Mortal Wkly Rep 1996;45(RR-9):1-41.
5. Blood modifiers. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1998:238-57.
6. Swain RA, Kaplan B, Montgomery E. Iron deficiency anemia: when is parenteral therapy warranted? Postgrad Med 1996;100:181-93.
7. Gross R, Schultink W, Juliawati. Treatment of anemia with weekly iron supplementation [Letter]. Lancet 1994;344:821.
8. Schultink W, Gross R, Gliwitzki M, Karyadi D, Matulessi P. Effect of daily vs twice weekly iron supplementation in Indonesian preschool children with low iron status. Am J Clin Nutr 1995;61:111-5.
9. Cook JD. Iron deficiency anemia. In: Brain MC, Carbone PP, eds. Current therapy in hematology-oncology. 3d ed. St. Louis: Mosby, 1988:9-11.
10. Massey AC. Microcytic anemia. Differential diagnosis and management of iron deficiency anemia. Med Clin North Am 1992;76:549-66.
11. Frewin R, Henson A, Provan D. ABC of clinical haematology. Iron deficiency anemia. BMJ 1997; 314:360-3.
12. Angeles IT, Gross R, Schultink W, Sastroamidjojo S. Is there a long-term effect of iron supplementation on anemia alleviation [Letter]? Am J Clin Nutr 1995;62:440-1.
13. Rudinskas L, Paton TW, Walker SE, Dotten DA, Cowan DH. Poor clinical response to entericcoated iron preparations. Can Med Assoc J 1989; 141:565-6.
14. American Medical Association, Division of Drugs and Toxicology. Hematinic agents. In: Drug evaluations annual 1995. 11th ed. Chicago: American Medical Association, 1995:2419-37.
15. Nishiyama S, Inomoto T, Nakamura T, Higashi A, Matsuda I. Zinc status relates to hematological deficits in women endurance runners. J Am Coll Nutr 1996;15:359-63.
16. Little DR. Hemochromatosis: diagnosis and management. Am Fam Physician 1996;53:2623-8.
17. 12 deficiency? QJM 1995;88:357-64.
18. Glass J. Iron deficiency anemia. In: Rakel RE, ed. Conn's Current therapy. 49th ed. Philadelphia: Saunders, 1997:349-52.
19. Gabrielli GB, De Sandre G. Excessive tea consumption can inhibit the efficacy of oral iron treatment in iron-deficiency anemia. Haematologica 1995;80: 518-20.
20. Ascari E. Iron-deficiency anemia resistant to iron therapy. Haematologica 1993;78:178-82.
21. 1999 Red book. Montvale, N.J.: Medical Economics Data, 1999.
22. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition 1995;11:163-8.
23. Jacobson RJ. Pernicious anemia and other megaloblastic anemias. In: Rakel RE, ed. Conn's Current therapy 49th ed. Philadelphia: Saunders, 1997: 358-62.
24. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine 1991;70:229-45.
25. Lederle FA. Oral cobalamin for pernicious anemia: medicine's best kept secret? JAMA 1991;265:94-5.
26. Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318:1720-8.
27. 12 metabolism and deficiency states. J Fam Pract 1995;41:595-600.
28. Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc 1994;69:144-50.
29. 12-deficient patients. Gastroenterology 1997;113:430-3.
30. Davenport J. Macrocytic anemia. Am Fam Physician 1996;53:155-62.
31. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41(RR-14):1-7.
32. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995;274:1698-702.
33. Swain RA, St. Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract 1997;44:138-44.
34. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
35. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276-82.
36. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
37. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
38. 12 to any folate fortification or supplement. Am J Clin Nutr 1997;65:572-3.